Drug General Information (ID: DDI2K15IF9)
Drug Name			Upadacitinib		Drug Info		Belantamab mafodotin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antirheumatics				Antineoplastics

Mechanism of Upadacitinib-Belantamab mafodotin Interaction (Severity Level: Major)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Upadacitinib				Belantamab mafodotin
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Upadacitinib and Belantamab mafodotin

Recommended Action
Management		Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.

References
1	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.